Literature DB >> 18612169

Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.

Dirk Strumberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18612169     DOI: 10.1200/JCO.2008.17.7410

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Epigenetic regulation in RCC: opportunities for therapeutic intervention?

Authors:  James Larkin; Xin Yi Goh; Marcus Vetter; Lisa Pickering; Charles Swanton
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

2.  Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.

Authors:  Christopher P Filson; Bruce G Redman; Rodney L Dunn; David C Miller
Journal:  Urology       Date:  2011-01-22       Impact factor: 2.649

3.  Advances in renal cell carcinoma treatment.

Authors:  Marc-Oliver Grimm; Ingmar Wolff; Stefan Zastrow; Michael Fröhner; Manfred Wirth
Journal:  Ther Adv Urol       Date:  2010-02

4.  Elucidation of the Molecular Mechanisms Underlying Sorafenib-Induced Hepatotoxicity.

Authors:  Abdullah F AlAsmari; Nemat Ali; Fawaz AlAsmari; Wael A AlAnazi; Faleh Alqahtani; Metab Alharbi; Farraj M Alotaibi; Abdullah A Aldossari; Mohammed AlSwayyed; Mohammed M Alanazi; Ali A Alshamrani
Journal:  Oxid Med Cell Longev       Date:  2020-05-14       Impact factor: 6.543

5.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.

Authors:  Ariel A Williams; John P T Higgins; Hongjuan Zhao; Börje Ljunberg; James D Brooks
Journal:  BMC Clin Pathol       Date:  2009-11-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.